Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is It Too Late to Jump In on Zentalis?

TheMotleyFool

0 0

Zentalis Pharmaceuticals (NASDAQ: ZNTL) stock closed at $52.22 on Friday, 26.4% higher than it did on Thursday. Such spikes are nothing new for this fast-climbing clinical-stage biopharmaceutical company, which specializes in small-molecule cancer drugs. If you had invested $5,000 in the company's IPO in April, when it was selling at $18 a share, you would have $14,505 today.

There's clearly a lot of hype regarding Zentalis, which was founded in 2014 and has its headquarters in New York City with a science center in San Diego.

Image source: Getty Images.

Source Fool.com

Like: 0

ZNTL

Share